YmAbs Therapeutics (YMAB)
(Delayed Data from NSDQ)
$12.37 USD
-0.44 (-3.43%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $12.37 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
YMAB 12.37 -0.44(-3.43%)
Will YMAB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for YMAB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for YMAB
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates
New Strong Buy Stocks for April 19th
YMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for April 17th
Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
Other News for YMAB
Y-mAbs Therapeutics Finalizes CFO Transition and Advisory Deal
Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer
Buy Rating for Y-Mabs: Unveiling the Growth Potential of Its Radioimmunotherapy Platform
Y-mAbs Therapeutics initiated with bullish view at Truist, here's why
Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting